Literature DB >> 16864815

A double-blind, controlled study of botulinum toxin A in chronic myofascial pain.

E Qerama1, A Fuglsang-Frederiksen, H Kasch, F W Bach, T S Jensen.   

Abstract

BACKGROUND: Recent studies have reported a potential analgesic effect of botulinum toxin A (BTXA) in musculoskeletal pain. The present double-blind, randomized, placebo-controlled, parallel clinical trial studied the effect of BTXA on pain from muscle trigger points and on EMG activity at rest and during voluntary contraction.
METHODS: Thirty patients with trigger points in the infraspinatus muscles received either 50 units/0.25 mL of BTXA or 0.25 mL of isotonic saline. Baseline measures were determined during a run-in period of 1 week. Outcome measures including local and referred spontaneous pain, pain detection and tolerance thresholds to mechanical pressure, and shoulder movement were assessed at 3 and 28 days after injection. The interference pattern of the EMG during maximal voluntary effort of infraspinatus muscle was recorded and a standardized search for spontaneous electrical motor endplate activity at the trigger points was performed before and 28 days after BTXA or saline injection.
RESULTS: BTXA reduced motor endplate activity and the interference pattern of EMG significantly but had no effect on either pain (spontaneous or referred) or pain thresholds compared with isotonic saline.
CONCLUSIONS: The results do not support a specific antinociceptive and analgesic effect of botulinum toxin A.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864815     DOI: 10.1212/01.wnl.0000224731.06168.df

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 2.  Botulinum toxin treatment of myofascial pain: a critical review of the literature.

Authors:  Robert Gerwin
Journal:  Curr Pain Headache Rep       Date:  2012-10

Review 3.  The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis.

Authors:  Tony Zhang; Aleem Adatia; Wasifa Zarin; Misha Moitri; Abi Vijenthira; Rong Chu; Lehana Thabane; Walter Kean
Journal:  Inflammopharmacology       Date:  2010-11-13       Impact factor: 4.473

Review 4.  Botulinum toxin for pain.

Authors:  Roberto Casale; Valeria Tugnoli
Journal:  Drugs R D       Date:  2008

Review 5.  An update on botulinum toxin A injections of trigger points for myofascial pain.

Authors:  Jon Y Zhou; Dajie Wang
Journal:  Curr Pain Headache Rep       Date:  2014-01

Review 6.  Alternatives to Opioids in the Pharmacologic Management of Chronic Pain Syndromes: A Narrative Review of Randomized, Controlled, and Blinded Clinical Trials.

Authors:  Andrea L Nicol; Robert W Hurley; Honorio T Benzon
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

Review 7.  Trigger Point Injections.

Authors:  Malathy Appasamy; Christopher Lam; John Alm; Andrea L Chadwick
Journal:  Phys Med Rehabil Clin N Am       Date:  2022-05       Impact factor: 2.391

Review 8.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Botulinum toxin for myofascial pain syndromes in adults.

Authors:  Adriana Soares; Régis B Andriolo; Alvaro N Atallah; Edina M K da Silva
Journal:  Cochrane Database Syst Rev       Date:  2014-07-25

10.  Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: a review from a clinical perspective.

Authors:  José M Climent; Ta-Shen Kuan; Pedro Fenollosa; Francisco Martin-Del-Rosario
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.